Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.

British journal of cancer - 9 May 2017

Calegari M A, Inno A, Monterisi S, Orlandi A, Santini D, Basso M, Cassano A, Martini M, Cenci T, de Pascalis I, Camarda F, Barbaro B, Larocca L M, Gori S, Tonini G, Barone C

Abstract excerpt

BACKGROUND: Presently, few options are available for refractory colorectal cancer (CRC). O6-methyl-guanine-DNA-methyltransferase (MGMT) promoter methylation is a frequent and early event in CRC tumourigenesis. This epigenetic silencing is a predictor of response to the alkylating drug temozolomide in glioblastoma. Preclinical evidences and some case reports showed temozolomide activity in CRC with MGMT silencing,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anemia
Share to Antineoplastic Agents, Alkylating

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dacarbazine

Share to DNA Modification Methylases

Share to Nausea

Share to Retreatment

Share to Temozolomide

Share to Vomiting

Source

Open in PubMed Open full text

Identifiers

PMID: 28427088
DOI: 10.1038/bjc.2017.109
PMCID: PMC5482728

Genes

MGMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.PMID 28427088Read ↗

Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylationSemantic proximity Read ↗

A Phase II Study of Temozolomide in Patients with Advanced Aerodigestive Tract and Colorectal Cancers and Methylation of the<i>O</i>6-Methylguanine-DNA Methyltransferase PromoterSemantic proximity Read ↗

Role of MGMT as biomarker in colorectal cancerSemantic proximity Read ↗

The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials.Semantic proximity Read ↗

The Role of miRNA for the Treatment of MGMT Unmethylated Glioblastoma MultiformeSemantic proximity Read ↗

Clinicopathological significance and potential drug target of O6-methylguanine-DNA methyltransferase in colorectal cancer: a meta-analysis.Semantic proximity Read ↗

Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft modelSemantic proximity Read ↗

An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting.Semantic proximity Read ↗

Effect of DNA methylation status on first-line anti-epidermal growth factor receptor treatment in patients with metastatic colorectal cancer.Semantic proximity Read ↗

Correlation between the promoter methylation status of ATP-binding cassette sub-family G member 2 and drug sensitivity in colorectal cancer cell linesSemantic proximity Read ↗

DNA methylation status as a biomarker of anti‐epidermal growth factor receptor treatment for metastatic colorectal cancerSemantic proximity Read ↗

miR-29c contribute to glioma cells temozolomide sensitivity by targeting O6-methylguanine-DNA methyltransferases indirectlySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.